Genolution

Genolution CROIC

The Cash Return on Invested Capital (CROIC) of Genolution (225220.KQ) as of Oct 22, 2026 is -10.90 %. In the previous year, Cash Return on Invested Capital (CROIC) was -13.05 % — a change of -16.49% (higher).

CROIC

-10.90 %

YoY

-16.49%

Last updated:

Cash Return on Invested Capital (CROIC) of Genolution is 2025 -10.90 % . Cash Return on Invested Capital (CROIC) of Genolution was 2024 -13.05 % . It decreases by -16.49% higher compared to the previous year.

The Genolution CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-60.59 KRW
Jan 1, 2019
-52.10 KRW
Jan 1, 2020
54.88 KRW
Jan 1, 2021
25.06 KRW
Jan 1, 2022
-8.19 KRW
Jan 1, 2023
-7.19 KRW
Jan 1, 2024
-13.05 KRW
Jan 1, 2025
-10.90 KRW
The Genolution CROIC history
YEARCROICYoY
-10.90 %-16.49%
-13.05 %+81.49%
-7.19 %-12.25%
-8.19 %-132.70%
25.06 %-54.34%
54.88 %-205.35%
-52.10 %-14.01%
-60.59 %+1,577.82%
-3.61 %-67.74%
-11.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Cash Return on Invested Capital (CROIC) of Genolution is -10.90 % in 2025.

Cash Return on Invested Capital (CROIC) of Genolution changed from -13.05 % to -10.90 %, representing a -16.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Genolution since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genolution

All Key Metrics — Genolution